Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Journal of Clinical Oncology · 01.04.2023 · 41 (10) · 1830-1840
DOI: 10.1200/jco.22.02186 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.04.2023. Verfasst von Roy S Herbst und 24 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 394-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. PURPOSE The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106 ) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non–small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of final DFS data. METHODS Overall, 682 patients with stage IB-IIIA (American Joint Committee on Cancer/Union for International Cancer Control, seventh edition) EGFR-mutated (exon 19 deletion/L858R) NSCLC were randomly assigned 1:1 (stratified by stage, mutational status, and race) to receive osimertinib 80 mg once-daily or placebo for 3 years. The primary end point was DFS by investigator assessment in stage II-IIIA disease analyzed by stratified log-rank test; following early reporting of statistical significance in DFS, no further formal statistical testing was planned. Secondary end points included DFS in stage IB-IIIA, overall survival, and safety. Patterns of recurrence and CNS DFS were prespecified exploratory end points. RESULTS At data cutoff (April 11, 2022), in stage II-IIIA disease, median follow-up was 44.2 months (osimertinib) and 19.6 months (placebo); the DFS HR was 0.23 (95% CI, 0.18 to 0.30); 4-year DFS rate was 70% (osimertinib) and 29% (placebo). In the overall population, DFS HR was 0.27 (95% CI, 0.21 to 0.34); 4-year DFS rate was 73% (osimertinib) and 38% (placebo). Fewer patients treated with osimertinib had local/regional and distant recurrence versus placebo. CNS DFS HR in stage II-IIIA was 0.24 (95% CI, 0.14 to 0.42). The long-term safety profile of osimertinib was consistent with the primary analysis. CONCLUSION These updated data demonstrate prolonged DFS benefit over placebo, reduced risk of local and distant recurrence, improved CNS DFS, and a consistent safety profile, supporting the efficacy of adjuvant osimertinib in resected EGFR-mutated NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT.
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
- Department of Medical Oncology, Austin Health, Melbourne, Australia.
- Klinik für Pneumologie-Evangelische Lungenklinik Berlin Buch, Berlin, Germany.
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Roy S Herbst, Yi-Long Wu, Jie Wang, Terufumi Kato, Jonathan W Goldman, Konstantin Laktionov, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Charuwan Akewanlop, Laura Bonanno, Manuel Domine, Damien Urban, Masahiro Tsuboi
Förderung
- NCATS NIH HHS
Zitieren
APA
Herbst, R. S., Wu, Y. L., John, T., Grohe, C., Majem, M., Wang, J., Kato, T., Goldman, J. W., Laktionov, K., Kim, S. W., Yu, C. J., Vu, H. V., Lu, S., Lee, K. Y., Mukhametshina, G., Akewanlop, C., de Marinis, F., Bonanno, L., Domine, M., …, & Tsuboi, M. (2023). Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of Clinical Oncology, 41(10), 1830-1840. https://doi.org/10.1200/jco.22.02186
Vancouver
Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of Clinical Oncology. 2023;41(10):1830-1840. doi:10.1200/jco.22.02186
BibTeX
@article{Herbst2023,
author = {Herbst, Roy S and Wu, Yi-Long and John, Thomas and Grohe, Christian and Majem, Margarita and Wang, Jie and Kato, Terufumi and Goldman, Jonathan W and Laktionov, Konstantin and Kim, Sang-We and Yu, Chong-Jen and Vu, Huu Vinh and Lu, Shun and Lee, Kye Young and Mukhametshina, Guzel and Akewanlop, Charuwan and de Marinis, Filippo and Bonanno, Laura and Domine, Manuel and Shepherd, Frances A and Urban, Damien and Huang, Xiangning and Bolanos, Ana and Stachowiak, Marta and Tsuboi, Masahiro},
title = {Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {10},
pages = {1830--1840},
doi = {10.1200/jco.22.02186}
}
EUVIMED